This site is intended for health professionals only
Sanofi-aventis, the French pharmaceutical firm, has said it may improve its offer to buy out Genzyme if the US biotech company undertakes negotiations.
According to Dow Jones news agency, a source at the firm said the board of Sanofi-aventis is not split on whether to increase its rejected $69 (£44) offer for each share and pursue the deal.
Apparently, the Sanofi board has agreed in principle that the offer can be improved but wants Genzyme to indicate it is happy to negotiate on it.
No spokesman for the French firm was available for comment.
Copyright Press Association 2010